HealthEx Immuno-Oncology is a high-profile forum designed for C-suite and board level executives, and key influential partners and stakeholders in oncology. For those leading the businesses fighting the most devastating human disease of our time.
This is a 40-person Chatham House Rule, formatted forum in which industry leaders discuss and shape the future of their sector behind closed doors. They are hollow-square formats and not your standard one-dimensional meeting format meaning all executives engage in meaningful strategic and sector debate and discussion. The forums will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole.
The 40 seats will be allocated with no fewer than 36 executives and KOLs, with the remaining seats taken by Forum Co-Hosts that may include 1 Pharma, 1 Global Advisory, 1 Law Firm, 1 CRO and / or 1 Investor. The GEO breakdown will roughly be 40 US, 50% UK and EU and 10% RoW and as we are focused on diversity, we are looking to ensure that at least 30% of the attendees are women Executives.
CEO, CFOs, CBOs and executives of oncology-focused life sciences companies developing treatments and cures for cancers. It is not for scientists, researchers and technical job titles in oncology.
CEOs and/or event partners put forward case studies – either success stories or current challenges and use the group as “consultants”. Each case study follows this format:
Headline – short and enticing
Nutshell – a concise statement of the issue
Background – the players, the issue, what was at stake, etc
What Was Tried? - what worked and what didn’t
Questions - clarifying questions from the group.
Review - what are you taking back with you? what will you try?
All the attendees in the room will be asked: “If you could have the answer to one question, that would fundamentally help change the way your business runs, what would it be?"
￼The questions will be scored– the highest score going to the question asked ￼by the most people, and that becoming the focus of the discussion.
Executives can explore in this session:
The Industry and Business Agenda
Innovating deal structures in oncology - M&A and licensing, addressing price and value in reimbursement, translation and commercialisation models
The R&D Agenda
Getting oncology drugs to patients faster, addressing immunotherapy’s limits of efficacy in a minority of patients and tumour types - advancing treatment ‘cocktails’ combining drugs, academic and industry collaboration
The Investment Agenda
Maintaining and growing funding and investment in oncology
The Future Agenda
Innovation in business models in oncology drug development, the latest innovations in oncology treatments, the digital health crossover
Are you interested in a seat at the table and would like to be considered for an invitation to attend the Immuno-Oncology Forum?